Yingxi Li

机构：Weifang Medical University, Sun Yat-sen University, China Pharmaceutical University, Chinese Academy of Sciences, TCM-Intigrated Cancer Center of Southern Medical University, China Academy of Chinese Medical Sciences, Sun Yat-sen University Cancer Center, University of Chinese Academy of Sciences · ORCID：0009-0007-4788-6282

发表论文 16 篇 · 总被引 27 次 · h-index 3

代表论文

• Priming with DNMT Inhibitors Potentiates PD-1 Immunotherapy by Triggering Viral Mimicry in Relapsed/Refractory NK/T-cell Lymphoma (2025 · Cancer Discovery · 被引 11)
• Dexmedetomidine preconditioning attenuates ferroptosis in myocardial ischemia-reperfusion injury via α2 adrenergic receptor activation (2024 · Heliyon · 被引 8)
• Effective Dexmedetomidine Dose for Stage N2 Sleep Induction and Associated Factors in Depression-Related Insomnia: A Polysomnography-Based Analysis (2025 · Nature and Science of Sleep · 被引 3)
• 800MO First report of BCL-2 inhibitor TQB3909 in pts with relapsed or refractory non-Hodgkin lymphoma (NHL) and acute myeloid leukemia (AML): Data from a phase I study (2024 · Annals of Oncology · 被引 2)
• Quality analysis of pediatric sleep testing from three hospitals in China (2017 · Sleep Medicine · 被引 2)
• The Association Between Shift Work, Sleep Quality, and Health-Related Quality of Life Among Workers in the Logistics Industry (2024 · Journal of Community Health · 被引 1)